AIM ImmunoTech Inc. - Expanded Access Programs

Expanded Access Intelligence

Official Statements

Score contribution: 100 — 1 supporting sources.

Score 1001 references

Featured Reference

Immuno-Oncology | AIM ImmunotechOpens in new window

“Ampligen is currently being used to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center.”

EAP Related Articles from Sponsor

Score contribution: 80 — 7 supporting sources.

Score 807 references

Featured Reference

Hemispherx Expands Ampligen Early Access Programme to ...Opens in new window

Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, said it amended its agreement with Netherlands-based myTomorrows to include management of a Special Access Programme (SAP) in Canada for patients suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

About | AIM ImmunotechSource

Ampligen is currently being used to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center.

Scientific Publications | AIM ImmunotechSource

Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program

Hemispherx Successfully Completes Production of More Than 8,500 ...Source

Hemispherx plans to generate substantial revenues from this large batch through an existing 2,100 vial stock order from myTomorrows for its early access programs. Further, this batch will supply the initial demand for the anticipated commercial launch of Ampligen in Argentina, where it is approved for treatment of severe ME/CFS. The recent Argentine approval is the first-ever approval of a drug for severe ME/CFS. Additionally, this large lot meets the Company’s projected needs for clinical trials of Ampligen in the United States, including the FDA-approved compassionate care program in ME/CFS, and clinical trials involving various cancers with Ampligen as a stand-alone therapy as well as in combination with checkpoint blockade technology.

Ampligen® | AIM ImmunotechSource

Ampligen is currently being used to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center.

Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech ...Source

Go here for a full report on Hemispherx’s ongoing Ampligen clinical trials, its Early Access Program for pancreatic cancer in Europe and its Expanded Access Program for ME/CFS in the United States.

Active EAPs on ClinicalTrials.gov

Score contribution: 60 — 1 supporting sources.

Score 601 references

Featured Reference

Ampligen in Chronic Fatigue SyndromeOpens in new window

Conditions: Chronic Fatigue Syndrome

Partner with Right2Hope

Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.

Talk to Our Team Explore Programs